PROFIT随机试验中危前列腺癌放疗后复发模式分析
基于PROFIT三期随机试验中法国和澳大利亚中心的中危前列腺癌患者,回顾性分析常规分割放疗与低分割放疗后生化复发患者的解剖复发部位。中位随访6.4年,共纳入274例(低分割组130例、常规分割组144例),两组复发率分别为24.3%和19.4%,各部位无进展生存期均无显著差异。
要点
- 低分割组复发35例(24.3%),常规分割组复发28例(19.4%),中位随访6.4年。
- 局部、盆腔淋巴结、盆腔外淋巴结和骨转移的中位复发时间分别为4.9年、3.96年、2.95年和3.6年。
- 低分割与常规分割放疗在局部、盆腔淋巴结、盆腔外淋巴结和骨无进展生存期上均无显著差异。
核心结论
- 低分割或常规分割放疗后复发率均较低,两种治疗在解剖复发模式上无可见差异。
- 作者认为考虑这些复发模式的个体化管理策略可优化中危患者的诊疗,包括初始分期和优势病灶的微boost。
研究设计与样本
- 研究基于PROFIT试验(NCT00304759)中法国和澳大利亚中心的中危前列腺癌患者,该试验为三期多中心随机对照试验。
- 采用分子正电子发射断层成像、磁共振成像和骨扫描,回顾性识别低分割或常规分割放疗后生化复发患者的解剖复发部位。
- 共纳入274例患者(低分割组130例,常规分割组144例),中位随访6.4年。
- 采用Kaplan-Meier分析比较两组局部无进展生存期、盆腔淋巴结无转移生存期、盆腔外淋巴结无转移生存期和骨无转移生存期。
主要发现
- 低分割组35例(24.3%)和常规分割组28例(19.4%)患者发生复发。
- 中位复发时间因部位而异:局部4.9年,盆腔淋巴结3.96年,盆腔外淋巴结2.95年,骨转移3.6年。
- 低分割与常规分割组在局部无进展生存期、盆腔淋巴结无转移生存期、盆腔外淋巴结无转移生存期和骨无转移生存期上均无显著差异。
临床怎么用
- 作者认为考虑这些复发模式的个体化管理策略可优化中危患者的诊疗,包括初始分期和优势病灶的微boost。
局限性
- 原文标题和摘要中明确标注为回顾性识别生化复发患者的解剖复发部位。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Conventionally fractionated radiation therapy (CFRT) and hypofractionated RT (HFRT) are established treatments for intermediate-risk (IR) prostate cancer (PCa), with differing dose per fraction. However, their comparative patterns of failure remain unclear. This stuy aims to analyze the distinct relapse patterns of HFRT versus CFRT in terms of local progression-free survival (LPFS), pelvic lymph node metastasis-free survival (pnMFS), extrapelvic lymph node MFS (epnMFS), and bone MFS (bMFS). METHODS AND MATERIALS: Patients with IR PCa included in French and Australian centers in the "PROstate Fractionated Irradiation Trial (PROFIT)" study (NCT00304759), a phase 3, multicenter, randomized controlled trial. Using molecular positron emission tomography imaging, magnetic resonance imaging, and bone scintigraphy, the anatomic sites of relapse were retrospectively identified in biochemically relapsing patients after HFRT or CFRT. LPFS, pnMFS, epnMFS, and bMFS were compared between both treatment arms using Kaplan-Meier analyses. RESULTS AND LIMITATIONS: With a median follow-up of 6.4 years, 274 patients (130 HFRT and 144 CFRT) were included, among whom 35 (24.3%) in the HFRT arm and 28 (19.4%) in the CFRT arm experienced relapse. Median time to relapse varied by site: 4.9 years locally, 3.96 years for pelvic lymph nodes, 2.95 years for extrapelvic lymph nodes, and 3.6 years for bone metastasis. No significant differences were found between HFRT and CFRT arms in LPFS, pnMFS, epnMFS, or bMFS. CONCLUSIONS: Relapse rates after HFRT or CFRT are low, with no discernible variance in anatomical relapse patterns between treatments. Tailored management strategies considering these relapse patterns could optimize care of IR patients, including initial staging and microboosting of dominant lesions.
引用
- Langé M, Campion L, Ollivier L, et al. Patterns of Relapse Following Radiation Therapy of Intermediate-Risk Prostate Cancer in the PROFIT Randomized Trial. Int J Radiat Oncol Biol Phys. 2025. PMID: 39914555. doi:10.1016/j.ijrobp.2025.01.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。